BMC Cancer has published this Collection on immunology and immunotherapy in solid cancers.
While surgery, chemotherapy, and radiation therapy have been the standard of care for solid cancer treatment for decades, these methods have often proved unable to provide durable disease control. Thus, immunotherapy could be the next core pillar in solid tumor treatment. However, clinical success with immunotherapy for solid tumors has often been very difficult to achieve due to several barriers, including immunosuppressive tumor microenvironment, inefficient trafficking, and heterogeneity of tumor antigens. A better understanding of the immune system and identifying new molecular targets would foster the development of novel, safe, and effective treatments for solid cancers.
In recognition of this relevant field, BMC Cancer has published this Collection which encouraged submissions addressing topics including, but not limited to:
• Cancer vaccines
• Immune checkpoint inhibition
• Investigations into mechanisms of immunosuppression in the tumor microenvironment
• Alternative immune mechanisms for treatment
• Immune modulatory combinations with standard-of-care therapies
• Cellular therapies and CAR T-Cells
• Innate and adaptive immune responses in cancer
• Impact of stromal population on cancer immunity and immunotherapy
• Solid tumor resistance to cell-based therapies
• Inflammation in the tumor and peritumoral microenvironment
Image credit: Juan Gärtner / stock.adobe.com
